drugset / Trial / NCT03829540
CD4CAR for CD4+ Leukemia and Lymphoma
Phase 1
Recruiting
20 enrolled
Huda Salman
National Institutes of Health (NIH) · collabiCell Gene Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is designed as a single arm open label Phase I, 3x3, multicenter study of CD4-directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory T-cell leukemia and lymphoma. Specifically, the study will evaluate the safety and feasibility of CD4CAR T-cells. Funding Source - FDA OOPD
Timeline
- Start
- 2020-07-09
- Primary completion
- 2027-12
- Completion
- 2042-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD4CAR | Cell therapy | 800000 cells | Intravenous |